PRESIDENTS

CLAUDIO CERCHIONE
ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO DEI TUMORI DINO AMADORI - IRCCS
ITALY

DAVID W. GREENING
BAKER HEART AND DIABETES INSTITUTE
LA TROBE UNIVERSITY
AUSTRALIA

GIOVANNI MARTINELLI
ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO DEI TUMORI DINO AMADORI - IRCCS
ITALY

ANTONIA REALE
MONASH UNIVERSITY
THE ALFRED
AUSTRALIA

ANDREW SPENCER
MONASH UNIVERSITY
THE ALFRED
AUSTRALIA

ANGELO VACCA
UNIVERSITÀ DEGLI STUDI DI BARI ALDO MORO
ITALY

SCIENTIFIC BOARD

C. CERCHIONE
D. W. GREENING
G. MARTINELLI
A. REALE
R. RIA
A. SPENCER
A. VACCA

SCIENTIFIC SECRETARIAT

C. CERCHIONE
D. W. GREENING
A. FRASSANITO
G. MARTINELLI
A. MELACCIO
A. REALE
G. SIMONETTI
A. G. SOLIMANDO
A. SPENCER
A. VACCA

soho Italy
SOCIETY OF HEMATOLOGIC ONCOLOGY



1ST JULY 2021

EXTRACELLULAR VESICLES AND THEIR ROLE IN PATIENTS WITH MULTIPLE MYELOMA

10,5 CME/ECM FOR: PHYSICIANS, BIOLOGISTS, BIOMEDICAL LABORATORY TECHNICIANS, NURSES

FREE REGISTRATION

SOHOITALY.IT

@SOHOITALY

PATRONAGE

ISTITUTO ROMAGNOLO PER LO STUDIO DEI TUMORI DINO AMADORI

SERVIZIO SANITARIO REGIONALE EMILIA-ROMAGNA
Azienda Unità Sanitaria Locale della Romagna

CGRSC CENTRAL CLINICAL SCHOOL GRADUATE RESEARCH STUDENT COMMITTEE

AIOM Associazione Italiana di Oncologia Medica

ACBD Australian Centre for Blood Diseases

SIES Società Italiana di Ematologia Sperimentale

SIE Società Italiana di Ematologia

SIMI Società Italiana di Medicina Interna

EVIta

MONASH University

AlfredHealth

SNEV Student Network on EVs

ISEV

IN ASSOCIATION WITH
soho SOCIETY OF HEMATOLOGIC ONCOLOGY

UNIVERSITÀ DEGLI STUDI DI BARI ALDO MORO

ORGANIZING SECRETARIAT
Pro eventi
info@proeventi.it
www.proeventi.it

IN THE PAST DECADE, THERE HAVE BEEN MAJOR ADVANCES IN THE TREATMENT OF THE BLOOD CANCER MULTIPLE MYELOMA (MM). THE INTRODUCTION OF NOVEL AGENTS SUCH AS IMMUNE-MODIFYING AGENTS (IMIDS), PROTEASOME INHIBITORS, MONOCLONAL ANTIBODIES, WITH OR WITHOUT STEM CELL TRANSPLANTATION, HAS RESULTED IN SIGNIFICANTLY IMPROVED PATIENT SURVIVAL. MEANWHILE, THE INCREASED UNDERSTANDING OF MM TUMOR BIOLOGY HAS PROVIDED A RATIONALE FOR NEW COMBINATIONS OF DRUGS AND RISK-ADAPTED AND INDIVIDUALIZED TREATMENTS TO FURTHER IMPROVE PATIENT MANAGEMENT.

EXTRACELLULAR VESICLES (EVS) ARE CELL-DERIVED MEMBRANOUS PARTICLES THAT MEDIATE CELL-TO-CELL COMMUNICATION BY TRANSFERRING PROTEINS, LIPIDS AND NUCLEIC ACIDS LOCALLY AND THROUGH SYSTEMIC CIRCULATION. EVS ARE ACTIVE REGULATORS IN THE CROSS-TALK BETWEEN MM TUMOUR CELLS AND BONE MARROW MICROENVIRONMENT, WITH THE CAPACITY TO ALTER ANGIOGENESIS, OSTEOCLAST DIFFERENTIATION AND IMMUNOSUPPRESSION, PROMOTING TUMOUR PROGRESSION AND DRUG RESISTANCE. CIRCULATING EVS CONTAINING TUMOUR-SPECIFIC MOLECULAR SIGNATURES (ONCOPROTEINS, RNAS, DNA FRAGMENTS) HAVE POTENTIAL CLINICAL UTILITY AS NEXT-GENERATION LIQUID BIOPSY BIOMARKERS IN CANCER DIAGNOSIS ANDMANAGEMENT, WITH THE POTENTIAL TO CHARACTERISE BOTH SPATIAL HETEROGENEITY AND CLONAL EVOLUTION THUS INFORMING NEW MODALITIES FOR DIAGNOSIS, RISK STRATIFICATION, MONITORING AND THERAPEUTIC INTERVENTION IN MM. HOWEVER, THE NANO-SCALE NATURE OF EVS AND THE COMPLEXITY OF BIOFLUIDS PRESENT CHALLENGES THAT NEED TO BE ADDRESSED BEFORE
THE POTENTIAL OF EVS AS BIOMARKERS AND THERAPEUTIC TARGETS CAN BE ACHIEVED.

THE ITALIAN SOCIETY OF HEMATOLOGIC ONCOLOGY (SOHO ITALY) WAS ESTABLISHED AS A NON-PROFIT ORGANIZATION IN 2019 TO PROMOTE WORLDWIDE RESEARCH (EDUCATION, PREVENTION, PRECLINICAL AND CLINICAL STUDIES AND PATIENT CARE) OF HEMATOLOGIC MALIGNANCIES AND RELATED DISORDERS. IN THIS SCENARIO, SOHO ITALY TOGETHER WITH AUSTRALIAN COLLEAGUES AIM TO BRING TOGETHER INTERNATIONAL EXPERTS TO DISCUSS THE LATEST ADVANCES IN THE PATHOPHYSIOLOGY AND THERAPY OF MM AND TO BETTER UNDERSTAND THE ROLE OF EVS IN PATIENTS WITH MM.

CENTRAL EUROPEAN SUMMER TIME

07.45 WHAT IS SOHO ITALY C. CERCHIONE G. MARTINELLI
07.50 OPENING REMARKS
C. CERCHIONE D. W. GREENING G. MARTINELLI A. REALE A. SPENCER A. VACCA

SESSION 1 - THE MULTIPLE MYELOMAS
H. EINSELE A. SPENCER G. MARTINELLI
08.00 THE MULTIPLE MYELOMAS - BIOLOGY, DIAGNOSIS, RISK STRATIFICATION **J.L. HAROUSSEAU**
08.20 ROLE OF MICROENVIRONMENT IN MM **A. VACCA**
08.40 IMMUNE SYSTEM IN MM **P. NERI**
09.00 VALIDATING NOVEL BH3 MIMETICS FOR THE TREATMENT OF MM **I. SAVVIDOU**
09.20 ORAL COMMUNICATION THROMBOPOIETIN PROMOTES ANGIOGENESIS AND DISEASE PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA **A.G. SOLIMANDO**
09.30 LECTURE LIQUID BIOPSY IN MM **A. SPENCER**

BREAK

SESSION 2 - UNDERSTANDING EXTRACELLULAR VESICLES
M. BEBAWY A. VACCA D. W. GREENING
10.20 EXTRACELLULAR VESICLES - OVERVIEW, UPDATE **K. WITWER**
10.40 EXTRACELLULAR VESICLES IN CANCER—IMPLICATIONS FOR FUTURE IMPROVEMENTS IN CANCER CARE **A. RAI**
11.00 EVS AS CANCER DIAGNOSTICS **A. MÖLLER**
11.20 EV BYSTANDER SIGNALING AND CANCER RESISTANCE **P. SAMUEL**
11.40 TOOLS FOR TRACKING BIODISTRIBUTION OF CANCER EVS **B. SUNG**
12.00 ORAL COMMUNICATION MODULATION OF POSITIVE AND NEGATIVE EFFECTORS INDUCED BY SOLUBLE AND MV- BOUND THERAPEUTIC ANTI-CD38 ANTIBODIES IN MULTIPLE MYELOMA **A. FAINI**
12.10 STUDENT/ECR NETWORK ON EVS (SNEV), OVERVIEW **A. NASIRI KENARI**

LUNCH

SESSION 3 - HOW I MANAGE MULTIPLE MYELOMA
K.C. ANDERSON C. CERCHIONE M.V. MATEOS
12.55 HOW I MANAGE FRONTLINE MM **M. V. MATEOS**
13.15 HOW I MANAGE RELAPSED/REFRACTORY MM **C. CERCHIONE**
13.35 BIOLOGICALLY BASED THERAPIES FOR MM **K.C. ANDERSON**
13.55 NEW TREATMENT AVENUES IN MM **H.C. LEE**
14.15 MANAGING INFECTIONS IN MM **R. RIA**
14.35 ORAL COMMUNICATION BONE AND EXTRAMEDULAR FORMS OF MULTIPLE MYELOMA: CLINICAL FEATURES IN PATIENTS OF GOMEL REGION OF BELARUS **Z. KOZICH**

BREAK

SESSION 4 - ROLE OF EXTRACELLULAR VESICLES IN MYELOMA
A. REALE G. SIMONETTI B. SUNG
14.55 EVS IN MM BONE DISEASE **K. VANDERKERKEN**
15.15 EVS IN MM PROGRESSION **A. ROCCARO**
15.35 MM FIBROBLASTS ENHANCE BONE MARROW ANGIOGENESIS VIA SMALL EVS RELEASE **I. SALTARELLA**
15.55 MM-SMALL EVS, OMICS, PLASMA **A. REALE**
16.15 ORAL COMMUNICATION UNCOVERING THE EXOSOMES DIVERSITY AS A STRATEGY FOR HAEMATOLOGICAL MALIGNANCIES MANAGEMENT **E. IACCINO**
16.25 LECTURE PROTEOMIC INSIGHTS IN EVS: KEY PLAYERS IN CANCER AND POTENTIAL THERAPEUTIC STRATEGY **D. W. GREENING**
16.55 CLOSING REMARKS C. CERCHIONE G. MARTINELLI A. VACCA

SUPPORTED BY AN UNRESTRICTED EDUCATIONAL GRANT FROM

Celgene | Bristol Myers Squibb™ Company
gsk
janssen Oncology
PHARMACEUTICAL COMPANIES OF Johnson&Johnson
Karyopharm® Therapeutics
Takeda

CANADA MOUNTAIN DAYLIGHT TIME

11.45PM WHAT IS SOHO ITALY C. CERCHIONE G. MARTINELLI
11.50PM (30TH JUNE) OPENING REMARKS
C. CERCHIONE D. W. GREENING G. MARTINELLI A. REALE A. SPENCER A. VACCA

SESSION 1 - THE MULTIPLE MYELOMAS
H. EINSELE A. SPENCER G. MARTINELLI
12.00AM THE MULTIPLE MYELOMAS - BIOLOGY, DIAGNOSIS, RISK STRATIFICATION **J.L. HAROUSSEAU**
12.20AM ROLE OF MICROENVIRONMENT IN MM **A. VACCA**
12.40AM IMMUNE SYSTEM IN MM **P. NERI**
01.00AM VALIDATING NOVEL BH3 MIMETICS FOR THE TREATMENT OF MM **I. SAVVIDOU**
01.20AM ORAL COMMUNICATION THROMBOPOIETIN PROMOTES ANGIOGENESIS AND DISEASE PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA **A.G. SOLIMANDO**
01.30AM LECTURE LIQUID BIOPSY IN MM **A. SPENCER**

BREAK

SESSION 2 - UNDERSTANDING EXTRACELLULAR VESICLES
M. BEBAWY A. VACCA D. W. GREENING
02.20AM EXTRACELLULAR VESICLES - OVERVIEW, UPDATE **K. WITWER**
02.40AM EXTRACELLULAR VESICLES IN CANCER—IMPLICATIONS FOR FUTURE IMPROVEMENTS IN CANCER CARE **A. RAI**
03.00AM EVS AS CANCER DIAGNOSTICS **A. MÖLLER**
03.20AM EV BYSTANDER SIGNALING AND CANCER RESISTANCE **P. SAMUEL**
03.40AM TOOLS FOR TRACKING BIODISTRIBUTION OF CANCER EVS **B. SUNG**
04.00AM ORAL COMMUNICATION MODULATION OF POSITIVE AND NEGATIVE EFFECTORS INDUCED BY SOLUBLE AND MV- BOUND THERAPEUTIC ANTI-CD38 ANTIBODIES IN MULTIPLE MYELOMA **A. FAINI**
04.10AM STUDENT/ECR NETWORK ON EVS (SNEV), OVERVIEW **A. NASIRI KENARI**

LUNCH

SESSION 3 - HOW I MANAGE MULTIPLE MYELOMA
K.C. ANDERSON C. CERCHIONE M.V. MATEOS
04.55AM HOW I MANAGE FRONTLINE MM **M. V. MATEOS**
05.15AM HOW I MANAGE RELAPSED/REFRACTORY MM **C. CERCHIONE**
05.35AM BIOLOGICALLY BASED THERAPIES FOR MM **K.C. ANDERSON**
05.55AM NEW TREATMENT AVENUES IN MM **H.C. LEE**
06.15AM MANAGING INFECTIONS IN MM **R. RIA**
06.35AM ORAL COMMUNICATION BONE AND EXTRAMEDULAR FORMS OF MULTIPLE MYELOMA: CLINICAL FEATURES IN PATIENTS OF GOMEL REGION OF BELARUS **Z. KOZICH**

BREAK

SESSION 4 - ROLE OF EXTRACELLULAR VESICLES IN MYELOMA
A. REALE G. SIMONETTI B. SUNG
06.55AM EVS IN MM BONE DISEASE **K. VANDERKERKEN**
07.15AM EVS IN MM PROGRESSION **A. ROCCARO**
07.35AM MM FIBROBLASTS ENHANCE BONE MARROW ANGIOGENESIS VIA SMALL EVS RELEASE **I. SALTARELLA**
07.55AM MM-SMALL EVS, OMICS, PLASMA **A. REALE**
08.15AM ORAL COMMUNICATION UNCOVERING THE EXOSOMES DIVERSITY AS A STRATEGY FOR HAEMATOLOGICAL MALIGNANCIES MANAGEMENT **E. IACCINO**
08.25AM LECTURE PROTEOMIC INSIGHTS IN EVS: KEY PLAYERS IN CANCER AND POTENTIAL THERAPEUTIC STRATEGY **D. W. GREENING**
08.35AM CLOSING REMARKS C. CERCHIONE G. MARTINELLI A. VACCA

SUPPORTED BY AN UNRESTRICTED EDUCATIONAL GRANT FROM

USA CENTRAL STANDARD TIME

12.45AM WHAT IS SOHO ITALY C. CERCHIONE G. MARTINELLI
12.50AM OPENING REMARKS
C. CERCHIONE D. W. GREENING G. MARTINELLI A. REALE A. SPENCER A. VACCA

SESSION 1 - THE MULTIPLE MYELOMAS

H. EINSELE A. SPENCER G. MARTINELLI
01.00AM THE MULTIPLE MYELOMAS - BIOLOGY, DIAGNOSIS, RISK STRATIFICATION **J.L. HAROUSSEAU**
01.20AM ROLE OF MICROENVIRONMENT IN MM **A. VACCA**
01.40AM IMMUNE SYSTEM IN MM **P. NERI**
02.00AM VALIDATING NOVEL BH3 MIMETICS FOR THE TREATMENT OF MM **I. SAVVIDOU**
02.20AM ORAL COMMUNICATION THROMBOPOIETIN PROMOTES ANGIOGENESIS AND DISEASE PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA **A.G. SOLIMANDO**
02.30AM LECTURE LIQUID BIOPSY IN MM **A. SPENCER**

BREAK

SESSION 2 - UNDERSTANDING EXTRACELLULAR VESICLES

M. BEBAWY A. VACCA D. W. GREENING
03.20AM EXTRACELLULAR VESICLES - OVERVIEW, UPDATE **K. WITWER**
03.40AM EXTRACELLULAR VESICLES IN CANCER—IMPLICATIONS FOR FUTURE IMPROVEMENTS IN CANCER CARE **A. RAI**
04.00AM EVS AS CANCER DIAGNOSTICS **A. MÖLLER**
04.20AM EV BYSTANDER SIGNALING AND CANCER RESISTANCE **P. SAMUEL**
04.40AM TOOLS FOR TRACKING BIODISTRIBUTION OF CANCER EVS **B. SUNG**
05.00AM ORAL COMMUNICATION MODULATION OF POSITIVE AND NEGATIVE EFFECTORS INDUCED BY SOLUBLE AND MV- BOUND THERAPEUTIC ANTI-CD38 ANTIBODIES IN MULTIPLE MYELOMA **A. FAINI**
05.10AM STUDENT/ECR NETWORK ON EVS (SNEV), OVERVIEW **A. NASIRI KENARI**

LUNCH

SESSION 3 - HOW I MANAGE MULTIPLE MYELOMA

K.C. ANDERSON C. CERCHIONE M.V. MATEOS
05.55AM HOW I MANAGE FRONTLINE MM **M. V. MATEOS**
06.15AM HOW I MANAGE RELAPSED/REFRACTORY MM **C. CERCHIONE**
06.35AM BIOLOGICALLY BASED THERAPIES FOR MM **K.C. ANDERSON**
06.55AM NEW TREATMENT AVENUES IN MM **H.C. LEE**
07.15AM MANAGING INFECTIONS IN MM **R. RIA**
07.35AM ORAL COMMUNICATION BONE AND EXTRAMEDULAR FORMS OF MULTIPLE MYELOMA: CLINICAL FEATURES IN PATIENTS OF GOMEL REGION OF BELARUS **Z. KOZICH**

BREAK

SESSION 4 - ROLE OF EXTRACELLULAR VESICLES IN MYELOMA

A. REALE G. SIMONETTI B. SUNG
07.55AM EVS IN MM BONE DISEASE **K. VANDERKERKEN**
08.15AM EVS IN MM PROGRESSION **A. ROCCARO**
08.35AM MM FIBROBLASTS ENHANCE BONE MARROW ANGIOGENESIS VIA SMALL EVS RELEASE **I. SALTARELLA**
08.55AM MM-SMALL EVS, OMICS, PLASMA **A. REALE**
09.15AM ORAL COMMUNICATION UNCOVERING THE EXOSOMES DIVERSITY AS A STRATEGY FOR HAEMATOLOGICAL MALIGNANCIES MANAGEMENT **E. IACCINO**
09.25AM LECTURE PROTEOMIC INSIGHTS IN EVS: KEY PLAYERS IN CANCER AND POTENTIAL THERAPEUTIC STRATEGY **D. W. GREENING**
09.35AM CLOSING REMARKS C. CERCHIONE G. MARTINELLI A. VACCA

SUPPORTED BY AN UNRESTRICTED EDUCATIONAL GRANT FROM

Celgene | Bristol Myers Squibb™ Company
gsk
janssen Oncology
PHARMACEUTICAL COMPANIES OF Johnson&Johnson
Karyopharm® Therapeutics
Takeda

USA EASTERN STANDARD TIME

01.45AM WHAT IS SOHO ITALY C. CERCHIONE G. MARTINELLI
01.50AM OPENING REMARKS
C. CERCHIONE D. W. GREENING G. MARTINELLI A. REALE A. SPENCER A. VACCA

SESSION 1 - THE MULTIPLE MYELOMAS

H. EINSELE A. SPENCER G. MARTINELLI
02.00AM THE MULTIPLE MYELOMAS - BIOLOGY, DIAGNOSIS, RISK STRATIFICATION **J.L. HAROUSSEAU**
02.20AM ROLE OF MICROENVIRONMENT IN MM **A. VACCA**
02.40AM IMMUNE SYSTEM IN MM **P. NERI**
03.00AM VALIDATING NOVEL BH3 MIMETICS FOR THE TREATMENT OF MM **I. SAVVIDOU**
03.20AM ORAL COMMUNICATION THROMBOPOIETIN PROMOTES ANGIOGENESIS AND DISEASE PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA **A.G. SOLIMANDO**
03.30AM LECTURE LIQUID BIOPSY IN MM **A. SPENCER**

BREAK

SESSION 2 - UNDERSTANDING EXTRACELLULAR VESICLES

M. BEBAWY A. VACCA D. W. GREENING
04.20AM EXTRACELLULAR VESICLES - OVERVIEW, UPDATE **K. WITWER**
04.40AM EXTRACELLULAR VESICLES IN CANCER—IMPLICATIONS FOR FUTURE IMPROVEMENTS IN CANCER CARE **A. RAI**
05.00AM EVS AS CANCER DIAGNOSTICS **A. MÖLLER**
05.20AM EV BYSTANDER SIGNALING AND CANCER RESISTANCE **P. SAMUEL**
05.40AM TOOLS FOR TRACKING BIODISTRIBUTION OF CANCER EVS **B. SUNG**
06.00AM ORAL COMMUNICATION MODULATION OF POSITIVE AND NEGATIVE EFFECTORS INDUCED BY SOLUBLE AND MV- BOUND THERAPEUTIC ANTI-CD38 ANTIBODIES IN MULTIPLE MYELOMA **A. FAINI**
06.10AM STUDENT/ECR NETWORK ON EVS (SNEV), OVERVIEW **A. NASIRI KENARI**

LUNCH

SESSION 3 - HOW I MANAGE MULTIPLE MYELOMA

K.C. ANDERSON C. CERCHIONE M.V. MATEOS
06.55AM HOW I MANAGE FRONTLINE MM **M. V. MATEOS**
07.15AM HOW I MANAGE RELAPSED/REFRACTORY MM **C. CERCHIONE**
07.35AM BIOLOGICALLY BASED THERAPIES FOR MM **K.C. ANDERSON**
07.55AM NEW TREATMENT AVENUES IN MM **H.C. LEE**
08.15AM MANAGING INFECTIONS IN MM **R. RIA**
08.35AM ORAL COMMUNICATION BONE AND EXTRAMEDULAR FORMS OF MULTIPLE MYELOMA: CLINICAL FEATURES IN PATIENTS OF GOMEL REGION OF BELARUS **Z. KOZICH**

BREAK

SESSION 4 - ROLE OF EXTRACELLULAR VESICLES IN MYELOMA

A. REALE G. SIMONETTI B. SUNG
08.55AM EVS IN MM BONE DISEASE **K. VANDERKERKEN**
09.15AM EVS IN MM PROGRESSION **A. ROCCARO**
09.35AM MM FIBROBLASTS ENHANCE BONE MARROW ANGIOGENESIS VIA SMALL EVS RELEASE **I. SALTARELLA**
09.55AM MM-SMALL EVS, OMICS, PLASMA **A. REALE**
10.15AM ORAL COMMUNICATION UNCOVERING THE EXOSOMES DIVERSITY AS A STRATEGY FOR HAEMATOLOGICAL MALIGNANCIES MANAGEMENT **E. IACCINO**
10.25AM LECTURE PROTEOMIC INSIGHTS IN EVS: KEY PLAYERS IN CANCER AND POTENTIAL THERAPEUTIC STRATEGY **D. W. GREENING**
10.35AM CLOSING REMARKS C. CERCHIONE G. MARTINELLI A. VACCA

SUPPORTED BY AN UNRESTRICTED EDUCATIONAL GRANT FROM

Celgene | Bristol Myers Squibb™ Company
gsk
janssen Oncology
PHARMACEUTICAL COMPANIES OF Johnson&Johnson
Karyopharm® Therapeutics
Takeda

AUSTRALIAN EASTERN STANDARD TIME

03.45PM WHAT IS SOHO ITALY C. CERCHIONE G. MARTINELLI
03.50PM OPENING REMARKS
C. CERCHIONE D. W. GREENING G. MARTINELLI A. REALE A. SPENCER A. VACCA

SESSION 1 - THE MULTIPLE MYELOMAS

H. EINSELE A. SPENCER G. MARTINELLI
04.00PM THE MULTIPLE MYELOMAS - BIOLOGY, DIAGNOSIS, RISK STRATIFICATION **J.L. HAROUSSEAU**
04.20PM ROLE OF MICROENVIRONMENT IN MM **A. VACCA**
04.40PM IMMUNE SYSTEM IN MM **P. NERI**
05.00PM VALIDATING NOVEL BH3 MIMETICS FOR THE TREATMENT OF MM **I. SAVVIDOU**
05.20PM ORAL COMMUNICATION THROMBOPOIETIN PROMOTES ANGIOGENESIS AND DISEASE PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA **A.G. SOLIMANDO**
05.30PM LECTURE LIQUID BIOPSY IN MM **A. SPENCER**

BREAK

SESSION 2 - UNDERSTANDING EXTRACELLULAR VESICLES

M. BEBAWY A. VACCA D. W. GREENING
06.20PM EXTRACELLULAR VESICLES - OVERVIEW, UPDATE **K. WITWER**
06.40PM EXTRACELLULAR VESICLES IN CANCER—IMPLICATIONS FOR FUTURE IMPROVEMENTS IN CANCER CARE **A. RAI**
07.00PM EVS AS CANCER DIAGNOSTICS **A. MÖLLER**
07.20PM EV BYSTANDER SIGNALING AND CANCER RESISTANCE **P. SAMUEL**
07.40PM TOOLS FOR TRACKING BIODISTRIBUTION OF CANCER EVS **B. SUNG**
08.00PM ORAL COMMUNICATION MODULATION OF POSITIVE AND NEGATIVE EFFECTORS INDUCED BY SOLUBLE AND MV- BOUND THERAPEUTIC ANTI-CD38 ANTIBODIES IN MULTIPLE MYELOMA **A. FAINI**
08.10PM STUDENT/ECR NETWORK ON EVS (SNEV), OVERVIEW **A. NASIRI KENARI**

LUNCH

SESSION 3 - HOW I MANAGE MULTIPLE MYELOMA

K.C. ANDERSON C. CERCHIONE M.V. MATEOS
08.55PM HOW I MANAGE FRONTLINE MM **M. V. MATEOS**
09.15PM HOW I MANAGE RELAPSED/REFRACTORY MM **C. CERCHIONE**
09.35PM BIOLOGICALLY BASED THERAPIES FOR MM **K.C. ANDERSON**
09.55PM NEW TREATMENT AVENUES IN MM **H.C. LEE**
10.15PM MANAGING INFECTIONS IN MM **R. RIA**
10.35PM ORAL COMMUNICATION BONE AND EXTRAMEDULAR FORMS OF MULTIPLE MYELOMA: CLINICAL FEATURES IN PATIENTS OF GOMEL REGION OF BELARUS **Z. KOZICH**

BREAK

SESSION 4 - ROLE OF EXTRACELLULAR VESICLES IN MYELOMA

A. REALE G. SIMONETTI B. SUNG
10.55PM EVS IN MM BONE DISEASE **K. VANDERKERKEN**
11.15PM EVS IN MM PROGRESSION **A. ROCCARO**
11.35PM MM FIBROBLASTS ENHANCE BONE MARROW ANGIOGENESIS VIA SMALL EVS RELEASE **I. SALTARELLA**
11.55PM MM-SMALL EVS, OMICS, PLASMA **A. REALE**
12.15AM ORAL COMMUNICATION UNCOVERING THE EXOSOMES DIVERSITY AS A STRATEGY FOR HAEMATOLOGICAL MALIGNANCIES MANAGEMENT **E. IACCINO**
12.25AM LECTURE PROTEOMIC INSIGHTS IN EVS: KEY PLAYERS IN CANCER AND POTENTIAL THERAPEUTIC STRATEGY **D. W. GREENING**
12.55AM CLOSING REMARKS C. CERCHIONE G. MARTINELLI A. VACCA

SUPPORTED BY AN UNRESTRICTED EDUCATIONAL GRANT FROM

Celgene | Bristol Myers Squibb Company
gsk
janssen Oncology
PHARMACEUTICAL COMPANIES OF Johnson&Johnson
Karyopharm Therapeutics
Takeda

NEW ZEALAND STANDARD TIME

05.45PM WHAT IS SOHO ITALY C. CERCHIONE G. MARTINELLI
05.50PM OPENING REMARKS
C. CERCHIONE D. W. GREENING G. MARTINELLI A. REALE A. SPENCER A. VACCA

SESSION 1 - THE MULTIPLE MYELOMAS
H. EINSELE A. SPENCER G. MARTINELLI
06.00PM THE MULTIPLE MYELOMAS - BIOLOGY, DIAGNOSIS, RISK STRATIFICATION **J.L. HAROUSSEAU**
06.20PM ROLE OF MICROENVIRONMENT IN MM **A. VACCA**
06.40PM IMMUNE SYSTEM IN MM **P. NERI**
07.00PM VALIDATING NOVEL BH3 MIMETICS FOR THE TREATMENT OF MM **I. SAVVIDOU**
07.20PM ORAL COMMUNICATION THROMBOPOIETIN PROMOTES ANGIOGENESIS AND DISEASE PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA **A.G. SOLIMANDO**
07.30PM LECTURE LIQUID BIOPSY IN MM **A. SPENCER**

BREAK

SESSION 2 - UNDERSTANDING EXTRACELLULAR VESICLES
M. BEBAWY A. VACCA D. W. GREENING
08.20PM EXTRACELLULAR VESICLES - OVERVIEW, UPDATE **K. WITWER**
08.40PM EXTRACELLULAR VESICLES IN CANCER—IMPLICATIONS FOR FUTURE IMPROVEMENTS IN CANCER CARE **A. RAI**
09.00PM EVS AS CANCER DIAGNOSTICS **A. MÖLLER**
09.20PM EV BYSTANDER SIGNALING AND CANCER RESISTANCE **P. SAMUEL**
09.40PM TOOLS FOR TRACKING BIODISTRIBUTION OF CANCER EVS **B. SUNG**
10.00PM ORAL COMMUNICATIONMODULATION OF POSITIVE AND NEGATIVE EFFECTORS INDUCED BY SOLUBLE AND MV- BOUND THERAPEUTIC ANTI-CD38 ANTIBODIES IN MULTIPLE MYELOMA **A. FAINI**
10.10PM STUDENT/ECR NETWORK ON EVS (SNEV), OVERVIEW **A. NASIRI KENARI**

LUNCH

SESSION 3 - HOW I MANAGE MULTIPLE MYELOMA
K.C. ANDERSON C. CERCHIONE M.V. MATEOS
10.55PM HOW I MANAGE FRONTLINE MM **M. V. MATEOS**
11.15PM HOW I MANAGE RELAPSED/REFRACTORY MM **C. CERCHIONE**
11.35PM BIOLOGICALLY BASED THERAPIES FOR MM **K.C. ANDERSON**
11.55PM NEW TREATMENT AVENUES IN MM **H.C. LEE**
12.15AM MANAGING INFECTIONS IN MM **R. RIA**
12.35AM ORAL COMMUNICATION BONE AND EXTRAMEDULAR FORMS OF MULTIPLE MYELOMA: CLINICAL FEATURES IN PATIENTS OF GOMEL REGION OF BELARUS **Z. KOZICH**

BREAK

SESSION 4 - ROLE OF EXTRACELLULAR VESICLES IN MYELOMA
A. REALE G. SIMONETTI B. SUNG
12.55AM EVS IN MM BONE DISEASE **K. VANDERKERKEN**
01.15AM EVS IN MM PROGRESSION **A. ROCCARO**
01.35AM MM FIBROBLASTS ENHANCE BONE MARROW ANGIOGENESIS VIA SMALL EVS RELEASE **I. SALTARELLA**
01.55AM MM-SMALL EVS, OMICS, PLASMA **A. REALE**
02.15AM ORAL COMMUNICATION UNCOVERING THE EXOSOMES DIVERSITY AS A STRATEGY FOR HAEMATOLOGICAL MALIGNANCIES MANAGEMENT **E. IACCINO**
02.25AM LECTURE PROTEOMIC INSIGHTS IN EVS: KEY PLAYERS IN CANCER AND POTENTIAL THERAPEUTIC STRATEGY **D. W. GREENING**
02.55AM CLOSING REMARKS C. CERCHIONE G. MARTINELLI A. VACCA

SUPPORTED BY AN UNRESTRICTED EDUCATIONAL GRANT FROM

Celgene | Bristol Myers Squibb™ Company
gsk
janssen Oncology
PHARMACEUTICAL COMPANIES OF Johnson&Johnson
Karyopharm® Therapeutics
Takeda